KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Regeneron Pharmaceuticals (REGN) over the last 12 years, with Q4 2025 value amounting to $2.9 billion.

  • Regeneron Pharmaceuticals' Accumulated Expenses rose 1382.22% to $2.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.9 billion, marking a year-over-year increase of 1382.22%. This contributed to the annual value of $2.9 billion for FY2025, which is 1382.22% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Accumulated Expenses of $2.9 billion as of Q4 2025, which was up 1382.22% from $3.0 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' 5-year Accumulated Expenses high stood at $3.0 billion for Q3 2025, and its period low was $1.5 billion during Q1 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $2.2 billion (2021), whereas its average is $2.3 billion.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Accumulated Expenses surged by 6054.1% in 2021, and later tumbled by 1283.84% in 2022.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Accumulated Expenses stood at $2.2 billion in 2021, then fell by 6.01% to $2.1 billion in 2022, then increased by 13.68% to $2.4 billion in 2023, then rose by 7.18% to $2.5 billion in 2024, then increased by 13.82% to $2.9 billion in 2025.
  • Its last three reported values are $2.9 billion in Q4 2025, $3.0 billion for Q3 2025, and $2.5 billion during Q2 2025.